Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 323


International Society for Pharmacoeconomics and Outcomes Research Comments on the American Society of Clinical Oncology Value Framework.

Malone DC, Berg NS, Claxton K, Garrison LP Jr, IJzerman M, Marsh K, Neumann PJ, Sculpher M, Towse A, Uyl-de Groot C, Weinstein MC.

J Clin Oncol. 2016 Jun 13. pii: JCO644328. [Epub ahead of print] No abstract available.


The Anticipated Clinical and Economic Effects of 90-90-90 in South Africa.

Walensky RP, Borre ED, Bekker LG, Resch SC, Hyle EP, Wood R, Weinstein MC, Ciaranello AL, Freedberg KA, Paltiel AD.

Ann Intern Med. 2016 May 31. doi: 10.7326/M16-0799. [Epub ahead of print]


Aflibercept vs. Ranibizumab: cost-effectiveness of treatment for wet age-related macular degeneration in Sweden.

Panchmatia HR, Clements KM, Hulbert E, Eriksson M, Wittrup-Jensen K, Nilsson J, Weinstein MC.

Acta Ophthalmol. 2016 Apr 7. doi: 10.1111/aos.12964. [Epub ahead of print]


The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.

Girouard MP, Sax PE, Parker RA, Taiwo B, Freedberg KA, Gulick RM, Weinstein MC, Paltiel AD, Walensky RP.

Clin Infect Dis. 2016 Mar 15;62(6):784-91. doi: 10.1093/cid/civ981. Epub 2015 Dec 9.


Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US.

Pei PP, Weinstein MC, Li XC, Hughes MD, Paltiel AD, Hou T, Parker RA, Gaynes MR, Sax PE, Freedberg KA, Schackman BR, Walensky RP.

HIV Clin Trials. 2015 Nov;16(6):207-18. doi: 10.1080/15284336.2015.1123942. Epub 2015 Dec 11.


Cost-effectiveness of Statin Therapy for ASCVD--Reply.

Pandya A, Weinstein MC, Gaziano TA.

JAMA. 2015 Nov 24;314(20):2191-2. doi: 10.1001/jama.2015.12928. No abstract available.


Cost-Effectiveness of Screening for Primary Aldosteronism and Subtype Diagnosis in the Resistant Hypertensive Patients.

Lubitz CC, Economopoulos KP, Sy S, Johanson C, Kunzel HE, Reincke M, Gazelle GS, Weinstein MC, Gaziano TA.

Circ Cardiovasc Qual Outcomes. 2015 Nov;8(6):621-30. doi: 10.1161/CIRCOUTCOMES.115.002002. Epub 2015 Nov 10.


Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.

Pandya A, Sy S, Cho S, Weinstein MC, Gaziano TA.

JAMA. 2015 Jul 14;314(2):142-50. doi: 10.1001/jama.2015.6822. Erratum in: JAMA. 2015 Oct 20;314(15):1647.


Despite High Cost, Improved Pneumococcal Vaccine Expected To Return 10-Year Net Savings Of $12 Billion.

Kohli MA, Farkouh RA, Maschio MJ, McGarry LJ, Strutton DR, Weinstein MC.

Health Aff (Millwood). 2015 Jul;34(7):1234-40. doi: 10.1377/hlthaff.2014.1274.


Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age.

Ciaranello AL, Doherty K, Penazzato M, Lindsey JC, Harrison L, Kelly K, Walensky RP, Essajee S, Losina E, Muhe L, Wools-Kaloustian K, Ayaya S, Weinstein MC, Palumbo P, Freedberg KA.

AIDS. 2015 Jun 19;29(10):1247-59. doi: 10.1097/QAD.0000000000000672.


The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection.

Linas BP, Barter DM, Morgan JR, Pho MT, Leff JA, Schackman BR, Horsburgh CR, Assoumou SA, Salomon JA, Weinstein MC, Freedberg KA, Kim AY.

Ann Intern Med. 2015 May 5;162(9):619-29. doi: 10.7326/M14-1313.


The lifetime medical cost savings from preventing HIV in the United States.

Schackman BR, Fleishman JA, Su AE, Berkowitz BK, Moore RD, Walensky RP, Becker JE, Voss C, Paltiel AD, Weinstein MC, Freedberg KA, Gebo KA, Losina E.

Med Care. 2015 Apr;53(4):293-301. doi: 10.1097/MLR.0000000000000308.


The clinical role and cost-effectiveness of long-acting antiretroviral therapy.

Ross EL, Weinstein MC, Schackman BR, Sax PE, Paltiel AD, Walensky RP, Freedberg KA, Losina E.

Clin Infect Dis. 2015 Apr 1;60(7):1102-10. doi: 10.1093/cid/ciu1159. Epub 2015 Jan 12.


HIV cure strategies: how good must they be to improve on current antiretroviral therapy?

Sax PE, Sypek A, Berkowitz BK, Morris BL, Losina E, Paltiel AD, Kelly KA, Seage GR 3rd, Walensky RP, Weinstein MC, Eron J, Freedberg KA.

PLoS One. 2014 Nov 14;9(11):e113031. doi: 10.1371/journal.pone.0113031. eCollection 2014. Erratum in: PLoS One. 2015;10(1):e0117762.


Analyzing overall survival in randomized controlled trials with crossover and implications for economic evaluation.

Jönsson L, Sandin R, Ekman M, Ramsberg J, Charbonneau C, Huang X, Jönsson B, Weinstein MC, Drummond M.

Value Health. 2014 Sep;17(6):707-13. doi: 10.1016/j.jval.2014.06.006. Review.


Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold.

Neumann PJ, Cohen JT, Weinstein MC.

N Engl J Med. 2014 Aug 28;371(9):796-7. doi: 10.1056/NEJMp1405158. No abstract available.


The hepatitis C cascade of care: identifying priorities to improve clinical outcomes.

Linas BP, Barter DM, Leff JA, Assoumou SA, Salomon JA, Weinstein MC, Kim AY, Schackman BR.

PLoS One. 2014 May 19;9(5):e97317. doi: 10.1371/journal.pone.0097317. eCollection 2014.


Cost effectiveness of a gene expression score and myocardial perfusion imaging for diagnosis of coronary artery disease.

Phelps CE, O'Sullivan AK, Ladapo JA, Weinstein MC, Leahy K, Douglas PS.

Am Heart J. 2014 May;167(5):697-706.e2. doi: 10.1016/j.ahj.2014.02.005. Epub 2014 Feb 22.


The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients.

Linas BP, Barter DM, Leff JA, DiLorenzo M, Schackman BR, Horsburgh CR, Assoumou SA, Salomon JA, Weinstein MC, Kim AY, Freedberg KA.

AIDS. 2014 Jan 28;28(3):365-76. doi: 10.1097/QAD.0000000000000093.


Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer.

Fust K, Li X, Maschio M, Barron R, Weinstein MC, Parthan A, Walli-Attaei M, Chandler DB, Lyman GH.

Gynecol Oncol. 2014 Jun;133(3):446-53. doi: 10.1016/j.ygyno.2014.03.014. Epub 2014 Mar 19.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk